Sectors & IndustriesHealthcare
Best Healthcare Stocks to Buy Now (2025)
Top healthcare stocks in 2025 ranked by overall Due Diligence Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

Sector: Healthcare
Ticker
Company
Exchange
Industry
Zen Rating
Market Cap
Price
1d %
EBITDA
P/E
D/E
Country
DD Score
NXGL
NEXGEL INC
NASDAQ
Medical Instruments & Supplies
$20.17M$2.502.04%-$2.29M-6.25x1.00
United States
ADAG
ADAGENE INC
NASDAQ
Biotechnology
$96.15M$2.04-4.23%-$28.44M-3.20x0.76
China
ADIL
ADIAL PHARMACEUTICALS INC
NASDAQ
Biotechnology
$7.57M$0.350.00%-$8.45M-0.33x0.22
United States
ADGM
ADAGIO MEDICAL HOLDINGS INC
NASDAQ
Medical Devices
$25.07M$1.630.31%-$62.27M-0.39x3.14
United States
PPBT
PURPLE BIOTECH LTD
NASDAQ
Biotechnology
$31.29M$0.610.33%$3.26MN/A0.07
Israel
SLXN
SILEXION THERAPEUTICS CORP
NASDAQ
Biotechnology
$2.61M$3.571.13%-$11.13M0.05x47.31
Israel

Healthcare Industries

IndustryStocks1d %1w %1m %1y %DD ScoreP/E ratioP/B RatioROEROAROCEUpside/DownsideConsensus
637+0.00%-0.05%+4.28%-48.39%-97.28x4.69x-106.22%-5.90%-9.54%+81.58%Strong Buy
56+0.05%+1.66%+0.38%-20.26%20.65x3.77x-3.54%+7.27%+15.75%+9.35%Buy
19+0.33%-0.06%+2.59%-10.66%37.55x6.02x+60.37%+10.42%+17.94%+41.73%Buy
76+0.34%+0.57%+2.73%-20.49%-27.69x2.24x+11.59%+4.57%+10.00%+34.48%Buy
11+0.03%-1.09%+1.98%-33.43%14.71x2.02x+15.85%+4.97%+11.53%+16.80%Buy
53+0.26%+0.77%-0.71%-53.88%85.39x4.12x+8.47%+5.46%+9.16%+26.70%Strong Buy
47+0.52%-0.27%+1.25%-30.69%15.87x4.80x-189.09%+6.89%+15.29%+18.16%Buy
142-0.82%-0.47%-1.49%-34.52%30.71x3.98x+13.93%+8.55%+10.12%+30.94%Strong Buy
10-0.22%-1.77%+1.56%+25.94%26.73x291.57x-9.10%+3.03%+18.79%+14.81%Buy
55-0.34%-1.32%-2.43%-67.86%29.74x3.30x+10.41%+8.32%+11.05%+26.39%Buy

Healthcare Stocks FAQ

What are the best healthcare stocks to buy right now in Sep 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:

1. Embecta (NASDAQ:EMBC)


Embecta (NASDAQ:EMBC) is the #1 top healthcare stock out of 1106 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Embecta (NASDAQ:EMBC) is: Value: A, Growth: A, Momentum: C, Sentiment: B, Safety: D, Financials: A, and AI: C.

Embecta (NASDAQ:EMBC) has a Due Diligence Score of 35, which is 10 points higher than the healthcare sector average of 25. It passed 12 out of 38 due diligence checks and has average fundamentals. Embecta has seen its stock lose -8.73% over the past year, overperforming other healthcare stocks by 32 percentage points.

Embecta has an average 1 year price target of $18.50, an upside of 22.84% from Embecta's current stock price of $15.06.

Embecta stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Embecta, 50% have issued a Strong Buy rating, 0% have issued a Buy, 50% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Livanova (NASDAQ:LIVN)


Livanova (NASDAQ:LIVN) is the #2 top healthcare stock out of 1106 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Livanova (NASDAQ:LIVN) is: Value: B, Growth: A, Momentum: C, Sentiment: B, Safety: B, Financials: B, and AI: A.

Livanova (NASDAQ:LIVN) has a Due Diligence Score of 17, which is -8 points lower than the healthcare sector average of 25. Although this number is below the industry average, our proven quant model rates LIVN as a "A".It passed 5 out of 33 due diligence checks and has weak fundamentals. Livanova has seen its stock return 6.92% over the past year, overperforming other healthcare stocks by 48 percentage points.

Livanova has an average 1 year price target of $60.75, an upside of 11.41% from Livanova's current stock price of $54.53.

Livanova stock has a consensus Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Livanova, 0% have issued a Strong Buy rating, 75% have issued a Buy, 25% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Infusystem Holdings (NYSEMKT:INFU)


Infusystem Holdings (NYSEMKT:INFU) is the #3 top healthcare stock out of 1106 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Infusystem Holdings (NYSEMKT:INFU) is: Value: C, Growth: B, Momentum: C, Sentiment: A, Safety: C, Financials: A, and AI: C.

Infusystem Holdings (NYSEMKT:INFU) has a Due Diligence Score of 29, which is 4 points higher than the healthcare sector average of 25. It passed 9 out of 33 due diligence checks and has average fundamentals. Infusystem Holdings has seen its stock return 52.34% over the past year, overperforming other healthcare stocks by 93 percentage points.

Infusystem Holdings has an average 1 year price target of $12.00, an upside of 22.7% from Infusystem Holdings's current stock price of $9.78.

Infusystem Holdings stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Infusystem Holdings, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the healthcare stocks with highest dividends?

Out of 72 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

1. Essa Pharma (NASDAQ:EPIX)


Essa Pharma (NASDAQ:EPIX) has an annual dividend yield of 833.02%, which is 820 percentage points higher than the healthcare sector average of 12.89%.

Essa Pharma's dividend payout ratio of 0% indicates that its high dividend yield might not be sustainable for the long-term.

2. Select Medical Holdings (NYSE:SEM)


Select Medical Holdings (NYSE:SEM) has an annual dividend yield of 14.99%, which is 2 percentage points higher than the healthcare sector average of 12.89%. Select Medical Holdings's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Select Medical Holdings's dividend has not shown consistent growth over the last 10 years.

Select Medical Holdings's dividend payout ratio of 35.1% indicates that its high dividend yield is sustainable for the long-term.

3. Cryo Cell International (NYSEMKT:CCEL)


Cryo Cell International (NYSEMKT:CCEL) has an annual dividend yield of 9.07%, which is -4 percentage points lower than the healthcare sector average of 12.89%.

Cryo Cell International's dividend payout ratio of -2,166.7% indicates that its high dividend yield might not be sustainable for the long-term.

Why are healthcare stocks down?

Healthcare stocks were down -0.05% in the last day, and down 0% over the last week. Co Diagnostics was the among the top losers in the healthcare sector, dropping -34.74% yesterday.

Co-Diagnostics shares are trading lower after the company announced a $3.8 million registered direct offering of 9.619 million shares at a price of $0.40 per share.

What are the most undervalued healthcare stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued healthcare stocks right now are:

1. Harmony Biosciences Holdings (NASDAQ:HRMY)


Harmony Biosciences Holdings (NASDAQ:HRMY) is the most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 55 points higher than the healthcare sector average of 16. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has dropped -17.39% in the past year. It has overperformed other stocks in the healthcare sector by 24 percentage points.

2. Puma Biotechnology (NASDAQ:PBYI)


Puma Biotechnology (NASDAQ:PBYI) is the second most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Puma Biotechnology has a valuation score of 43, which is 27 points higher than the healthcare sector average of 16. It passed 3 out of 7 valuation due diligence checks.

Puma Biotechnology's stock has gained 66.92% in the past year. It has overperformed other stocks in the healthcare sector by 108 percentage points.

3. Embecta (NASDAQ:EMBC)


Embecta (NASDAQ:EMBC) is the third most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Embecta has a valuation score of 57, which is 41 points higher than the healthcare sector average of 16. It passed 4 out of 7 valuation due diligence checks.

Embecta's stock has dropped -8.73% in the past year. It has overperformed other stocks in the healthcare sector by 32 percentage points.

Are healthcare stocks a good buy now?

50.37% of healthcare stocks rated by analysts are a strong buy right now. On average, analysts expect healthcare stocks to rise by 41.77% over the next year.

4.6% of healthcare stocks have a Zen Rating of A (Strong Buy), 12.51% of healthcare stocks are rated B (Buy), 45.81% are rated C (Hold), 26.45% are rated D (Sell), and 10.63% are rated F (Strong Sell).

What is the average p/e ratio of the healthcare sector?

The average P/E ratio of the healthcare sector is 9.66x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.